These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1157 related articles for article (PubMed ID: 6239686)

  • 1. Immunomodulation and therapeutic characterization of thymosin fraction five.
    Talmadge JE; Uithoven KA; Lenz BF; Chirigos M
    Cancer Immunol Immunother; 1984; 18(3):185-94. PubMed ID: 6239686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five).
    Talmadge JE; Benedict KL; Uithoven KA; Lenz BF
    Immunopharmacology; 1984 Feb; 7(1):17-26. PubMed ID: 6232241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymosin: immunomodulatory and therapeutic characteristics.
    Talmadge JE
    Prog Clin Biol Res; 1984; 161():457-65. PubMed ID: 6237369
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin alpha 1 enhances while thymosin beta 4 suppresses the human autologous and allogeneic mixed lymphocyte reaction.
    Baxevanis CN; Reclos GJ; Perez S; Kokkinopoulos D; Papamichail M
    Immunopharmacology; 1987 Apr; 13(2):133-41. PubMed ID: 2954929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biological effect of three thymosin fraction 5 polypeptides in the murine mixed lymphocyte reaction.
    Baxevanis CN; Perez S; Kokkinopoulos D; Papamichail M
    Immunology; 1985 Apr; 54(4):723-30. PubMed ID: 3156810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of thymosin. I. Thymosin fraction 5 increases lymphokine production by mature murine T cells responding in a mixed lymphocyte reaction.
    Zatz MM; Goldstein AL
    J Immunol; 1985 Feb; 134(2):1032-8. PubMed ID: 3155533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory and therapeutic properties of bestatin in mice.
    Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
    Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressive effect of thymosin fraction 5 on proliferation of cultured human T lymphocytes.
    Wolf RE; Maca RD
    Immunopharmacology; 1986 Dec; 12(3):233-40. PubMed ID: 3493229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
    Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
    Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymosin-induced differentiation of murine thymocytes in allogeneic mixed lymphocyte cultures.
    Cohen GH; Hopper JA; Goldstein AL
    Ann N Y Acad Sci; 1975 Feb; 249():145-53. PubMed ID: 165764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
    Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
    Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymosin modulation of suppressor function in mice and man.
    Serrou B; Rosenfeld C; Caraux J; Thierry C; Cupissol D; Goldstein A
    Ann N Y Acad Sci; 1979; 332():95-100. PubMed ID: 161154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.
    Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Schlick E; Ruffmann R; Wiltrout RH; Chirigos MA
    Cancer Res; 1985 Mar; 45(3):1058-65. PubMed ID: 3155990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
    Roberts LK
    J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of murine thymocyte cytotoxic T cell responses by thymosin.
    Zatz MM; Goldstein AL
    Immunopharmacology; 1983 Jun; 6(1):65-74. PubMed ID: 6603447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.
    Mastino A; Favalli C; Grelli S; Innocenti F; Garaci E
    Cell Immunol; 1991 Mar; 133(1):196-205. PubMed ID: 1991327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells.
    Shrivastava P; Singh SM; Singh N
    J Biomed Sci; 2004; 11(5):623-30. PubMed ID: 15316138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells.
    Nicholl M; Lodge A; Brown I; Sugg SL; Shilyansky J
    J Pediatr Surg; 2004 Jun; 39(6):941-6; discussion 941-6. PubMed ID: 15185230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
    Ting CC; Rodrigues D
    J Natl Cancer Inst; 1982 Oct; 69(4):867-72. PubMed ID: 6214653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a novel chimera tumor necrosis factor (TNF-STH) constructed by connecting rTNF-S with thymosin beta 4 against murine syngeneic tumors.
    Noguchi K; Inagawa H; Tsuji Y; Morikawa A; Mizuno D; Soma G
    J Immunother (1991); 1991 Apr; 10(2):105-11. PubMed ID: 2043590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.